Reviewer’s report

Title: A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

Version: 1 Date: 3 August 2009

Reviewer: Lanny Rosenwasser

Reviewer’s report:

1- This is an acceptable report on a phase 1 trial of a humanized monoclonal to IL-13 emphasizing safety and pharmacokinetics. No data of biologic plausibility for this agent is evident from the report.

2- The dominance of IL-13, even over IL-4 as well as other mediators, in human asthma is less established and certainly not proven so that it’s place as atherapeutically effective strategy is still untested even wth this study.

3- The sentence at the top of page 3 lacks punctuation.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.